Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Tests Reported in Natera's CLIA Laboratories by Year
Tests Reported in Natera's CLIA Laboratories (tests)
Natera Tests Reported in Natera's CLIA Laboratories: 3,288,600.00 tests in FY2025, up 14.7% from a year earlier.
Latest, FY2025
3,288,600.00
Period ended Dec 31, 2025
Change on a year earlier
+14.7%
2,867,400.00 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“During the year ended December 31, 2025, total reported units were approximately 3,342,500, comprised of approximately 3,288,600 tests reported in our laboratories.”
Source: Form 10-K (FY2025) ↗
Reported in Form 10-K/10-Q MD&A (2019–2026Q2).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tests Reported in Natera's CLIA Laboratories (tests) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,288,600.00 | +14.7% | Form 10-K (FY2025) ↗ |
| FY2024 | Dec 31, 2024 | 2,867,400.00 | +23.4% | Form 10-K (FY2025) ↗ |
| FY2023 | Dec 31, 2023 | 2,323,400.00 | +24.8% | Form 10-K (FY2024) ↗ |
| FY2022 | Dec 31, 2022 | 1,861,000.00 | +32.9% | Form 10-K (FY2023) ↗ |
| FY2021 | Dec 31, 2021 | 1,400,100.00 | +53.4% | Form 10-K (FY2022) ↗ |
| FY2020 | Dec 31, 2020 | 912,500.00 | +27.0% | Form 10-K (FY2021) ↗ |
| FY2019 | Dec 31, 2019 | 718,500.00 | – | Form 10-K (FY2020) ↗ |
Cite this data
StockData. (2026). Natera Tests Reported in Natera's CLIA Laboratories, annual FY2019–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-tests-reported-lab
See every metric in the Natera KPI table. Data updated Nov 2, 2026.